Fetching results...
0 items found

P0821: Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial

Prof. Dr. J.E. (Jürgen) Gschwend
Gschwend J.E.1, Bajorin D.2, Galsky M.3, Broughton E.4, Braverman J.4, Koon H.5, Maira-Arce M.6, Hamilton M.4, Shi L.7, Guo S.7, Witjes J.A.8
1Technical University of Munich, Dept. of Urology, Munich, Germany, 2Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America, 3Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Division of Hematology and Medical Oncology, New York, United States of America, 4Bristol Myers Squibb, Dept. of Worldwide Health Economics and Outcomes Research, Princeton, United States of America, 5Bristol Myers Squibb, Clinical Development, Princeton, United States of America, 6Bristol Myers Squibb, Worldwide Medical, Princeton, United States of America, 7Evidera, Dept. of Evidence Synthesis, Modeling and Communication, Waltham, United States of America, 8Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands
36th Annual EAU Congress
Date – Time - Location
11 July 2021, 15:00 - 16:00, Virtual Room 7
Poster Session 28 - MIBC: Evolution of surgical management and morbidity
Urothelial Cancer, MIBC - Treatment, Drug Treatment
  • © 2023 European Association of Urology
  • Disclaimer